Idatb.com

CURRICULUM VITAE

PERSONAL INFORMATION
Name:
Infectious Disease Associates of Tampa Bay St. Joseph’s Comprehensive Research Institute 4200 N. Armenia Avenue, Suites 3 & 5
EDUCATION

College:
University of South Florida College of Medicine
POST GRADUATE TRAINING
Residency:
University of South Florida College of Medicine Fellowship: University of South Florida College of Medicine Infectious Diseases and Tropical Diseases
LICENSURE AND CERTIFICATES

Diplomate, National Board of Medical Examiners, 1991.
Diplomate, American Board of Internal Medicine, 1993.
Diplomate Infectious Diseases, American Board of Internal Medicine, 1996.

HONORS

Phi Beta Kappa, Emory University, Atlanta, Georgia, 1986.
Magna Cum Laude, Emory University, Atlanta, Georgia, 1986.
Joseph Collins Foundation Scholarship, University of South Florida
College of Medicine, 1988.
Outstanding Resident on Rotation, Department of Internal Medicine
University of South Florida College of Medicine, Tampa, Florida, 1992.

EXPERIENCE

Associate, International Travelers Clinic of Tampa Bay, Tampa, Florida, 1995 - present.
Associate, Infectious Diseases Associates of Tampa Bay, Tampa, Florida, 1995 - present.
HOSPITAL APPOINTMENTS

Medical Director, St. Joseph’s Hospital Tampa Care Clinic
4200 North Armenia Avenue, Tampa, Florida 33607 (1997 – present)
Associate Director, St. Joseph’s Hospital Tampa Care Clinic
4200 North Armenia Avenue, Tampa, Florida 33607 (1995 – 1997)
Associate Director, St. Anthony’s Pinellas Care Clinic, St. Petersburg, Florida 1998-present.

PROFESSIONAL ORGANIZATIONS

Associate, American College of Physicians, 1990-present.
American Medical Association, 1988-present.
American Society of Internal Medicine, 1991-1993.
Florida Infectious Disease Society, 1994-present.
Associate, Infectious Disease Society of America, 1994-present.
Society of Health Care Epidemiology of America, 1994-present.

ACADEMIC APPOINTMENTS

Clinical Assistant Professor, Department of Internal Medicine, University of South Florida
College of Medicine, Tampa, Florida, 1995 - present.
Attending Physician, Private Medicine Teaching Service, University of South Florida College of
Medicine, Tampa, Florida, 1995 - present.

HOSPITAL COMMITTEES

Member, Infection Control Committee, St. Joseph’s Hospital, Tampa, Florida, 1996- present.
Member, Infection Control Committee, Town and Country Hospital, Tampa, Florida, 1995-1998.
Member, Infection Control Committee, Vencor Hospital, Tampa, Florida, 1995-1998.
Member, Pharmacy and Therapeutics Review Committee, St. Joseph’s Hospital, Tampa, Florida,
1995-1998.
Member, Pharmacy and Therapeutics Review Committee, Vencor Hospital, Tampa, Florida,
1996 - 1998.
Member, HIV Steering Committee, St. Joseph’s Hospital, Tampa, Florida, 1996- 1998.
Member, Special Care/Pharmacy Committee, Town n Country Hospital, 1996- 1998.
Member, ICU Committee, St. Joseph’s Hospital, Tampa, Florida, 2000

ASSOCIATED ACTIVITIES

Member, Association of Private Physicians (APP), Tampa, Florida, 1996-1997.

MISCELLANEOUS

Ubillos SS: Food Poisoning, Southern Medical Association, Dial Access Program, 1994.

ABSTRACTS

Vila I, Ubillos S, Sander L: CD4 Lymphopenia, Honorable Mention, American College of
Physicians Annual Meeting, Orlando, Florida, 1993.
Larkin JA, Ubillos SS, Sinnott JT, Houston SH: Chemoprophylaxis Following Occupational
Exposure to HIV: A Simple Approach, Infections in Urology, 10(1):9-11,29,[email protected] SCP
Communications, Inc.)

PUBLICATIONS

Ubillos SS: Book Review, Sexually Transmitted Diseases, second edition, handbook, Journal of
the American Medical Association, April 19, Vol. 273, No. 15, 1995.
Ubillos SS, Vuong D, Sinnott J: Seabather’s Eruption, Southern Medical Journal, November
11:64, 1995.
Larkin J, Ubillos S: AZT Prophylaxis Protocol, Infection in Urology, in publication, 1996.
Larkin J, Ubillos S: AZT Prophylaxis Protocol, AIDS Reader, in publication, 1996.

GRANTS

Ubillos S: “A Randomized Study of the Long-Term Suppression of Plasma HIV Levels by Triple
Combination Regimens in Treatment Naive Subjects” A1454-148 PD: December 2, 1997.
RESEARCH STUDIES

Principal Investigator
Ubillos S: “A Randomized Study of the Long- Term Suppression of Plasma HIV Levels by
Triple Combination Regimens in Treatment Naïve Subjects” A1454-148
A Pilot Multi-Center Open label Study to Determine the Efficacy and Safety of Serostim in HIV
Patients with Unintentional Weight Loss or BCM Depletion on combination Antiretroviral
Therapy with or without Protease Inhibitors.
A Multi- Center, randomized, open-label, study of the safety and efficacy of Interferon alfa-2b
plus ribavirin for the treatment of HCV infection in HIV-infected persons: Daily versus TIW
interferon dosing HRN HCV/HIV Co-Infection Protocol VERSION 2.1 (PR 98-29-002)
A Multi-Center, Randomized, Controlled Study of the Biological Actions if Ampligen as an
Adjunct to HAART in HIV Disease. AMP 719.
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART: A Multi-center,
Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval. AMP
720.
An open-labeled study to evaluate the effect of every other week Procrit (Epoetin alfa) dosing on
maintaining quality of life and target hemoglobin levels in anemic HIV-infected patients. PRO1-
29-024; Phase IV.
Co-Investigator
A Phase 2 Randomized Study Investigating the Safety, Efficacy, and Pharmacokinetics of
Daptomycin 6mg/kg and 8mg/kg versus Comparator (vancomycin or Teicoplanin) in the
Treatment of Subjects Undergoing Surgical Standard of Care for Osteomyelitits Associated with
an Infected Prosthetic Hip or Knee Joint caused by Methicillin-resistant Staphylococcus aureus
and/or Coagulase-negative staphylococci.
The Norvir/Indinavir Combination Evaluation Study: A Randomized, Controlled, Open-Label
Comparison of Continuing Indinavir Q8H vs. Switching to Norvir/Indinavir 400ma/400 mg BID
(The Nice Study). PROTOCOL NO. M99-047.
A Phase II double-blind, Placebo-Controlled Dose Ranging Study To Assess The Antiretroviral
Activity And Safety Of DMP 266 In Combination With Open-Label Zidovudine (ZDV) And
Lamivudine (3TC) In HIV-Infected Patients without prior therapy.
A Randomized, Parallel Arm, Comparative, Open-Label, Multicenter Study of the Activity and
Safety of Two Formulations of Saquinavir in Combination with Two Nucleoside Antiretroviral
Drugs In Treatment of Naïve Patients.
A Randomized Blinded Study of the Antiretroviral Effect and Safety of Didanosine (ddI) + Stavudine (d4T) +/- Indinavir (IDV) in Treatment of Naïve HIV- Infected Subjects. A Randomized, double-blind Study of the Antiviral Activity of Once-Daily and Twice-Daily Dosing of Didanosine in Combination with Twice-Daily Dosing of Stavudine in HIV Infected Subjects. A Phase III, double-blind, Placebo-Controlled, Multicenter Study to Determine The Effectiveness And Tolerability Of The Combination of DMP 266And Indinavir Versus Indinavir In HIV- Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy. A Phase II, Randomized, double-blind, Placebo-Controlled Study of Lamotrigine (Lamictal) in the Treatment of Painful Peripheral Neuropathy in HIV Positive Individuals. A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Combination Regimens (DMP 266+ Indinavir, DMP 266+ Zidovudine + Lamivudine, Indinavir + Zidovudine + Lamivudine) I HIV- Infected Patients. Sponsored by DuPont Merck Pharmaceuticals. Protocol DMP 266-006. A Randomized, double-blind Study of the Antiviral Activity of Once-Daily and Twice-Daily Dosing of Didanosine in Combination With Twice-Daily Dosage of Stavudine I HIV Infected Subjects to show equivalent antiviral activity to assess the magnitude and duration of changes in CD4 cell counts, and to determine the short term tolerability of the Didanosine and d4T regimens. A Phase III, Multicenter, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three combination Regimens (Efavirenz + Stavudine + Didanosine, Abacavir+ Lamivudine + NRTI, Stavudine + Didanosine +Indinavir) in HIV-Infected Patients. A rollover study for DMP 266-006. Comparative Safety and Efficacy of Cefditoren Pivoxil and Clarithromycin in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis. HMR 3647A/3007 A Multicenter, randomized, double-blind comparative study of oral HMR 3647 (800 mg once daily) versus oral cefuroxime axetil (500 mg twice daily) for the treatment of acute exacerbation of chronic bronchitis in adults. A Phase IIIB, Open-Label, Randomized Study of the Effective of an Education Intervention on Virologic Outcomes, Adherence, Immunologic Outcome and Health Outcomes in HIV- infected Subjects from Under-represented Populations Treated with Nucleoside Therapy (Combivir, Lamivudine 150 mg/zidovudine 300 Mg Po Bid Plus Abacavir 300 Mg Po Bid) for Twenty-four weeks. An Abacavir (1592U89) Open Label Protocol for Adult Patients with HIV-1 Infection-Part B (Protocol CNAA3008). A Randomized, double-blind, Double Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of SB-268005 320 mg Once Daily Versus Cefurozime 500 mg plus
Clarithromycin 500 mg Twice Daily for 7 to 14 days in the Treatment of Bacterial Community
Acquired Pneumonia (CAP) in Adults.
Prospective, randomized, double-blind, Multicenter comparison of safety and efficacy of
sequential (IV to PO) BAY 12-803339 400/400 mg QD for 7-14 days versus sequential Tablets
200/200 mg QD for 7-14 in the treatment of patients with community acquired pneumonia.
A Phase III, Multicenter, Open-Label Study to Compare Antiretroviral Activity and Tolerability
of Three combination Regimens (Efavirenz + Stavudine + Didanosine, Abacavir+ Lamivudine +
NRTI, Stavudine + Didanosine + Indinavir) in HIV-infected Patients. A rollover study for DMP
266-006.
Comparative Safety and Efficacy of Cefditoren Pivoxil and Clarithromycin in the Treatment of
Acute Bacterial Exacerbation of Chronic Bronchitis.

UNIVERSITY AND COMMUNITY PRESENTATIONS

“What’s Happening With Herpes”, St. Joseph’s Tampa Care Center, Tampa, Florida, 1995.
“Sexually Transmitted Diseases”, University of South Florida College of Physicians, Division of
Infectious Diseases, Tampa, Florida, 1996.
“Cephalosporins in the Treatment of Serious Bacterial Infections”, University Community
Hospital, Tampa, Florida, 1996.
“Therapeutic Areas of Infectious Disease”, Access Medical Care, Tampa, Florida, 1996.
“Community Acquired Pneumonia”, MacDill Air Force Base, Tampa, Florida, 1996.
“HIV/AIDS Update”, Department of Internal Medicine, St. Joseph’s Hospital, Tampa, Florida,
1997.
“HIV/AIDS Update”, Department of Surgery, St. Joseph’s Hospital, Tampa, Florida, 1997.
“HIV/AIDS Update”, Department of Pulmonology, St. Joseph’s Hospital, Tampa, Florida, 1997.
“Vancomycin-Resistant Enterococcus (VRE)”, Vencor Hospital, Tampa, Florida, 1997.
“Methicillin-Resistant Staph Aureus (MRSA)”, Vencor Hospital, Tampa, Florida, 1997.
“HIV/AIDS Update”, Department of Obstetrics and Gynecology, St. Joseph’s Hospital, Tampa,
Florida, 1997.
“Top 10 Infectious Disease Stories of 1997”, St. Joseph’s Hospital, Tampa, Florida, 1998.
“HIV/AIDS Update”, Department of Family Practice, St. Joseph’s Hospital, Tampa, Florida, 1998. “HIV/AIDS Update”, Department of Neurology, St. Joseph’s Hospital, Tampa, Florida, 1999. “HIV/AIDS Update”, Medical Staff, Naples Community Hospital, Naples, Florida, 1999. “HIV/AIDS Update”, Annual Medical Staff Meeting, Tampa General Hospital, Wyndham Hotel, Tampa, Florida, 1999. “Domestic Violence Update”, Annual Medical Staff Meeting, Tampa General Hospital, Wyndham Hotel, Tampa, Florida, 1999. “HIV/AIDS Update”, Annual Medical Staff Meeting, St. Joseph’s Hospital, Tampa Florida, 1999. “HIV/AIDS Update”, Grand Rounds, Sun Coast Medical Group, St. Petersburg Clinic, St. Petersburg, Florida, 1999. “Highlights for South Africa: An Update from the 13th International AIDS Conference”, St. Joseph’s Hospital, Tampa Care, Pinellas Care Clinic and Comprehensive Research Institute, Tampa, Florida, 2000. “AIDS Epidemic Update” for World AIDS Day, St. Joseph’s Hospital, Tampa, Florida, 2005. “Top 10 Infectious Disease News Stories of 2005”, St. Joseph’s Hospital Grand Rounds, Tampa, Florida, 2006. “DECAIDS – Update on HIV”, Tampa, Florida, 2006. “MRSA – Community and Hospital Acquired MRSA”, Microbiology Dept Tampa General Hospital, Tampa, Florida, 2006. “Hepatitis C Update”, St. Joseph’s Hospital Grand Rounds, Tampa, Florida, 2006. “Emerging Infectious Diseases – Risk for First Responders”, Annual Meeting, Tampa, Florida, 2007. “Top 10 ID News Stories of 2006”, St. Joseph’s Hospital Grand Rounds, Tampa, Florida, 2007. “Top 10 ID News Stories of 2007”, St. Joseph’s Hospital Grand Rounds, Tampa, Florida, 2008. “HIV Jeopardy”, St. Joseph’s Hospital Grand Rounds, Tampa, Florida, 2008. “World AIDS Day Update”, St Joseph’s Hospital, Tampa, Florida, 2008. “HIV Trivia Game”, 18th Annual HIV Conference of Florida/Caribbean AETC, Orlando, Florida, 2009.

Source: http://www.idatb.com/pdf/Ubillos.pdf

nerys-centre-femmes.ch

LES HORMONES BIO-IDENTIQUES LES HORMONES BIO-IDENTIQUES sont le traitement alternatif des déséquilibres hormonaux et des troubles de la ménopause : Des hormones naturelles à la place du traitement synthétique de substitution hormonale. En général, quand on parle de traitement hormonal de substitution, on parle donc d’un traitement médicamenteux n’ayant rien à voir avec les hormones

Méthodes séparatives : synthèse et étude de nouvelles phases stationnaires pour la chromatographie liquide et l'électrophorèse capillaire

Méthodes Séparatives : synthèse et étude de nouvelles phases stationnaires pour la chromatographie liquide et l'électrophorèse capillaire Extrait du L' Institut des Sciences Moléculaires - Université Bordeaux - CNRS Méthodes Séparatives : synthèse et étude de nouvelles phases stationnaires pour la chromatographie liquide et l'électrophorèse capillaire Date de mise

Copyright ©2010-2018 Medical Science